Dasatinib

This publication has 11 references indexed in Scilit:

• Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
  New England Journal of Medicine, 2006
• The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants
  Cancer Research, 2006
• Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays
  Journal of Medicinal Chemistry, 2004
• Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells
  Nature Medicine, 2004
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
  Science, 2004
• BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
  Blood, 2003
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
  Cancer Cell, 2002
• Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
  Nature Reviews Drug Discovery, 2002
• Chronic Myeloid Leukemia
  New England Journal of Medicine, 1999
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
  Nature Medicine, 1996